Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJCAR19 in Pediatric and Young Adult Patients With Relapsed or Refractory CD19+ ALL
NCT03573700Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 2018
- Primary completion
- Jul 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SJCAR19 in acute lymphoblastic leukemia (ALL), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Tolerated Dose and Dose-limiting Toxicities at 4 weeks and Complete Response Rate at 4 weeks. Started Jul 2018; status: active, not recruiting.
02
Drugs
SJCAR19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03573700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573700.